Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
FibroBiologics, Inc. Common Stock (FBLG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/25/2025: FBLG (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -42.51% | Avg. Invested days 6 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/25/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 34.59M USD | Price to earnings Ratio - | 1Y Target Price 12.75 |
Price to earnings Ratio - | 1Y Target Price 12.75 | ||
Volume (30-day avg) 292146 | Beta - | 52 Weeks Range 0.86 - 13.59 | Updated Date 04/1/2025 |
52 Weeks Range 0.86 - 13.59 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.55 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -60.75% | Return on Equity (TTM) -559.73% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 26502556 | Price to Sales(TTM) - |
Enterprise Value 26502556 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 36408400 | Shares Floating 25127335 |
Shares Outstanding 36408400 | Shares Floating 25127335 | ||
Percent Insiders 23.2 | Percent Institutions 16.98 |
Analyst Ratings
Rating 4.33 | Target Price 12.75 | Buy 2 | Strong Buy 1 |
Buy 2 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
FibroBiologics, Inc. Common Stock
Company Overview
History and Background
FibroBiologics, Inc. is a biotechnology company focused on the development of innovative regenerative medicine therapies. Founded in [hypothetical year, replace with actual year], the company has focused on utilizing fibroblast cells for therapeutic applications, with milestones including preclinical studies, clinical trial initiations, and securing patents.
Core Business Areas
- Fibroblasts-Based Therapies: Development of fibroblast-based therapies for various diseases, including degenerative disc disease, wound healing, and cancer therapy. This segment focuses on research, preclinical and clinical trials, and eventual commercialization.
Leadership and Structure
The company has a leadership team comprised of scientists, medical professionals, and business executives experienced in biotechnology and regenerative medicine. The organizational structure likely includes research and development, clinical operations, regulatory affairs, and business development departments.
Top Products and Market Share
Key Offerings
- CYGNUSu2122 MSC-Secretome Product Family: CYGNUSu2122 are human umbilical cord-derived MSC-secretome products for research. Competitors include Thermo Fisher Scientific, Merck, and Lonza.
- Fibroblasts for Degenerative Disc Disease: FibroBiologics is developing fibroblast-based therapies for degenerative disc disease. Although the company is still in clinical trials, this would compete with traditional treatments (surgery, physical therapy, pain management) and other regenerative therapies. Market share is currently negligible, but expected to grow upon FDA approval. Competitors include DiscGenics, Mesoblast, and other companies developing cell-based therapies for DDD.
Market Dynamics
Industry Overview
The regenerative medicine industry is rapidly growing, driven by an aging population and increased demand for innovative therapies. Key trends include cell-based therapies, gene therapies, and biomaterials.
Positioning
FibroBiologics is positioning itself as a leader in fibroblast-based regenerative medicine, focusing on proprietary technologies and innovative therapies.
Total Addressable Market (TAM)
The regenerative medicine TAM is expected to reach hundreds of billions of dollars by [projected year]. FibroBiologics' positioning is to capture a significant portion of the market for fibroblast-based therapies through clinical trial success and commercialization.
Upturn SWOT Analysis
Strengths
- Proprietary fibroblast technology platform
- Strong research and development capabilities
- Focus on unmet medical needs
- Experienced management team
Weaknesses
- Limited clinical trial data to date
- High reliance on research and development funding
- Potential regulatory hurdles
- Competition from established players
Opportunities
- Expansion into new therapeutic areas
- Partnerships with pharmaceutical companies
- Increasing demand for regenerative medicine therapies
- Positive clinical trial results
Threats
- Regulatory changes
- Competition from other regenerative medicine companies
- Failure of clinical trials
- Economic downturn affecting investment
Competitors and Market Share
Key Competitors
- MESO
- BMY
- GSK
Competitive Landscape
FibroBiologics faces competition from established pharmaceutical companies and other regenerative medicine firms. Advantages include proprietary technology. Disadvantages include limited resources and clinical trial experience.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is dependent on preclinical and clinical development, data is unavailable.
Future Projections: Future growth will be driven by clinical trial success and commercialization of therapies. Analyst estimates unavailable.
Recent Initiatives: Recent initiatives likely include progressing clinical trials, expanding research and development efforts, and seeking partnerships.
Summary
FibroBiologics is a company with a promising proprietary technology in the regenerative medicine space. It is competing with bigger more established companies and it has a ways to go before it can capture a larger market share. The company is in early stages of clinical trials, which has both a lot of opportunity and risk. Future success will be dependent on strong clinical trial outcomes and the ability to grow the company with limited resouces.
Similar Companies
- MESO
- BMY
- GSK
Sources and Disclaimers
Data Sources:
- Company website, SEC filings, Industry reports.
- ChatGPT
Disclaimers:
This analysis is based on available information and should not be considered financial advice. Data is hypothetical and may not reflect actual results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About FibroBiologics, Inc. Common Stock
Exchange NASDAQ | Headquaters Houston, TX, United States | ||
IPO Launch date 2024-01-31 | Founder, Chairperson & CEO Mr. Peter O'Heeron | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.fibrobiologics.com |
Full time employees - | Website https://www.fibrobiologics.com | ||
FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.